NephroGenex - Innovative Therapies for Kidney Disease
Home Company - go there Product Candidate - go there Pharmaceutical Companies - go there Clinicians - go there News - go there Contact - go there
  HOME


NephroGenex is a drug-development company focusing on kidney disease.

The Company is developing Pyridorin™ (pyridoxamine dihydrochloride) as a treatment to slow the progression of diabetic kidney disease.

Pyridorin™ has demonstrated a significant treatment effect in slowing the progression of diabetic nephropathy in three Phase 2 clinical trials, and it has been awarded Fast Track status by the FDA. Pyridorin™ is one of the leading drug candidates in advanced clinical trials for diabetic kidney disease.

NephroGenex has reached an agreement with the FDA on a new Phase 3 program that provides for an accelerated regulatory pathway for Pyridorin approval.

Pharmaceutical Industry - go here
Pharmaceutical Industry >>

"Chronic kidney disease (CKD) represents an enormous burden on the health care system of the U.S. with treatment costs exceeding $24 billion"

(U.S. Renal Data System. USRDS 2005 Annual Data Report. National Institutes of Health, National Institute of Diabetes and Digestive Kidney Disease: Bethesda, MD, 2005)

 

 
Nephrogenex, Inc – 79 T.W. Alexander Drive, Building 4401, Suite 290 – P.O. Box 14188 – Research Triangle Park, NC 27709-4188.
air max 90 mp4 player